Lupia Tommaso, Pallotto Carlo, Corcione Silvia, Boglione Lucio, De Rosa Francesco Giuseppe
Infectious Diseases Unit, Cardinal Massaia Hospital, 14100 Asti, Italy.
Infectious Diseases Unit 1, Santa Maria Annunziata Hospital, Central District, Tuscany Health Care, Bagno a Ripoli, 500012 Florence, Italy.
Antibiotics (Basel). 2021 Feb 8;10(2):170. doi: 10.3390/antibiotics10020170.
Ceftobiprole combines an excellent spectrum for community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP) pathogens, with a low/medium MDR risk, and the β-lactams' safety in frail patients admitted to the hospital in internal medicine wards which may be at high risk of adverse events by anti-MRSA coverage as oxazolidinones or glycopeptides. We aimed to report the available evidence regarding ceftobiprole use in pneumonia and invasive bacterial infections, shedding light on ceftobiprole stewardship. The clinical application and real-life experiences of using ceftobiprole for bloodstream infections, including infective endocarditis, are limited but nevertheless promising. In addition, extended-spectrum ceftobiprole activity, including , , and , has theoretical advantages for use as empirical therapy in bacteremia potentially caused by a broad spectrum of microorganisms, such as catheter-related bacteremia. In the future, the desirable approach to sepsis and severe infections will be administered to patients according to their clinical situation, the intrinsic host characteristics, the susceptibility profile, and local epidemiology, while the "universal antibiotic strategy" will no longer be adequate.
头孢托罗对社区获得性肺炎（CAP）和医院获得性肺炎（HAP）病原体具有优异的抗菌谱，多重耐药风险低/中等，对于入住内科病房的体弱患者，其安全性与β-内酰胺类药物相当，而这些患者使用恶唑烷酮类或糖肽类药物进行抗耐甲氧西林金黄色葡萄球菌（MRSA）覆盖时可能发生不良事件的风险较高。我们旨在报告有关头孢托罗在肺炎和侵袭性细菌感染中应用的现有证据，以阐明头孢托罗的管理问题。头孢托罗用于血流感染（包括感染性心内膜炎）的临床应用和实际经验有限，但仍颇具前景。此外，头孢托罗的广谱活性，包括对[此处原文缺失具体菌名]、[此处原文缺失具体菌名]和[此处原文缺失具体菌名]的活性，在作为由多种微生物（如导管相关菌血症）引起的菌血症的经验性治疗方面具有理论优势。未来，针对脓毒症和严重感染的理想治疗方法将根据患者的临床情况、内在宿主特征、药敏谱和当地流行病学情况进行，而“通用抗生素策略”将不再适用。
